Patents
Literature
2 results about "Coxsackievirus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Coxsackievirus is a virus that belongs to a family of nonenveloped, linear, positive-sense single-stranded RNA viruses, Picornaviridae and the genus Enterovirus, which also includes poliovirus and echovirus. Enteroviruses are among the most common and important human pathogens, and ordinarily its members are transmitted by the fecal-oral route. Coxsackieviruses share many characteristics with poliovirus. With control of poliovirus infections in much of the world, more attention has been focused on understanding the nonpolio enteroviruses such as coxsackievirus.
Composition for treating rhinovirus infectious diseases, comprising GPR40 agonist as active ingredient
PCT designated stageWO2026135226A1Organic active ingredientsCosmetic preparationsViral infectious diseaseTherapeutic effect
The present invention relates to a composition for treating rhinovirus infectious diseases, comprising a GPR40 agonist as an active ingredient. Viruses causing cold symptoms include coronaviruses, picomaviruses, rhinoviruses, coxsackieviruses, adenoviruses, parainfluenza viruses, respiratory syncytial viruses, enteroviruses and the like, but since there is no universal antiviral agent capable of treating all types of viruses, application of the most appropriate therapeutic agent should vary depending on the virus causing the cold symptoms. The GPR40 agonist provided in the present invention exhibits a remarkable therapeutic effect on cold diseases caused by rhinovirus infection, and thus is expected to be actively used in the medical and healthcare fields.
Owner:UI (UNIVERSITY IND FOUNDATION) YONSEI UNIVERSITY
Preparation and application of a live attenuated Coxsackievirus A6 vaccine vector
PendingCN122081401AInactivation/attenuationMicroorganism based processesHighly pathogenicCoxsackievirus
This invention provides an attenuated vaccine against Coxsackievirus A6 (CVA6), its preparation method, and its application. By comparing a highly pathogenic clinical isolate (CVA6-HeB) with an attenuated strain (CVA6-TW141), the genetic basis of CVA6 virulence was systematically studied. This invention located the core virulence determinant to the P1 capsid region and identified a key lethal amino acid residue (VP3-238) that significantly weakens viral replication in target tissues. Based on this discovery, this invention designed and validated a candidate attenuated live vaccine with significantly reduced lethality.
Owner:SHANGHAI INSTITUTE OF INFECTIOUS DISEASE & BIOSECURITY